OS Therapies Inc (OSTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, OS Therapies reported revenue of $0. Net income was -$28.8M, or -$0.98 per diluted share. Operating activities generated -$14.2M of cash, leaving -$14.2M of free cash flow. At fiscal year end, OS Therapies held $6.8M in total assets against $11.9M in total liabilities.
Open the full interactive OS Therapies financials → Quarterly statements, key ratios, valuation history and price charts.
OS Therapies Key Stats
| Share Price | $1.45 |
|---|---|
| Market Cap | $63.7M |
| 52-Week Range | $1.16 – $2.24 |
| Shares Outstanding | 4.8 million (basic, 2026 Q1) |
OS Therapies Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Income | -$6.8M | -$28.7M |
| Pre-Tax Income | -$8.9M | -$28.8M |
| Net Income | -$8.9M | -$28.8M |
| Diluted EPS | -$0.88 | -$0.98 |
OS Therapies Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$6.9M | -$13.5M | -$10.4M | -$8.6M |
| Diluted EPS | -$0.21 | -$0.46 | -$0.27 | -$0.20 |
OS Therapies Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Current Assets | $5.5M | $332,912 |
| Total Assets | $5.5M | $6.8M |
| Current Liabilities | $4.6M | $11.8M |
| Total Liabilities | $4.7M | $11.9M |
| Shareholders' Equity | -$5.2M | -$6.1M |
OS Therapies Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$7.3M | -$14.2M |
| Cash From Investing | — | -$466,423 |
| Cash From Financing | $12.8M | $9.4M |
| Free Cash Flow | — | -$14.2M |
Figures from OS Therapies' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full OS Therapies financials page for every line item.
OS Therapies Company Profile
| Ticker | OSTX |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Rockville, Maryland |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001795091 |
Frequently Asked Questions
What was OS Therapies' revenue in fiscal 2025?
OS Therapies (OSTX) reported revenue of $0 for fiscal 2025.
What was OS Therapies' net income in fiscal 2025?
OS Therapies reported net income of -$28.8M for fiscal 2025.
What was OS Therapies' earnings per share (EPS) in fiscal 2025?
OS Therapies' diluted EPS was -$0.98 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did OS Therapies generate in fiscal 2025?
OS Therapies generated -$14.2M of free cash flow in fiscal 2025.
What was OS Therapies' revenue last quarter?
In its most recent reported quarter (2026 Q2), OS Therapies reported revenue of $0.
How many shares of OS Therapies are outstanding?
OS Therapies reported a weighted average of 4.8 million basic shares outstanding in 2026 Q1.
What is OS Therapies' market cap?
Based on its latest closing price, OS Therapies (OSTX) has a market capitalization of about $63.7M.
When does OS Therapies' fiscal year end?
OS Therapies' fiscal year end, as registered with the SEC, is December 31.
Where is OS Therapies headquartered?
OS Therapies lists its business address in Rockville, Maryland in its SEC filings.